Thursday, August 30, 2012
|Attorney General's lawsuit against Janssen Pharmaceuticals Inc. and Johnson & Johnson|
|Final judgment and permanent injunction against Janssen Pharmaceuticals Inc. and Johnson & Johnson|
Under the settlement, the State of Texas will receive $11.37 million. Additionally, the settlement prohibits Janssen from unlawfully marketing the antipsychotics drugs subject to the agreement. For a five-year period, Janssen must also:
Employ scientifically trained personnel to develop medical content to be provided in its communications to providers, rather than sales and marketing professionals.
Clearly disclose the specific risks identified in the products’ black-box warnings on promotional materials for its atypical antipsychotic drugs.
Develop policies to ensure that financial incentives are not given to sales and marketing staff that promote off-label marketing.
Require that medical education providers disclose any financial support they receive from Janssen to aid their programs.
Earlier this year, the Texas Attorney General’s Office resolved the State’s civil Medicaid fraud case against Janssen, which resolved claims made to doctors of Medicaid patients, and resulted in a $61 million recovery for the State of Texas and state taxpayers. Today’s agreement resolves the misrepresentations made to doctors of non-Medicaid patients.